UPPSALA, Sweden, Oct. 23, 2003 (PRIMEZONE) --
Interim report January - September 2003 Uppsala, Sweden, October 23, 2003. Pyrosequencing AB (Stockholm: PYRO A) today reported results for the first nine months 2003.
Highlights (Figures in brackets refer to the same period 2002) - Sales during the period amounted to 68.6 MSEK (63.4 MSEK) - Operating result excluding non-recurring items for the period was - 116.7 MSEK (-117.4 MSEK) - Result after tax was -189.6 MSEK (-120.6 MSEK) for the period - Earnings per share amounted to - 5.44 SEK (-3.47 SEK) for the period - The acquisition of Personal Chemistry was approved by an extraordinary general meeting, the integration is progressing according to plan - Sale of an exclusive license for whole genome sequencing to 454 Life Sciences for a minimum of 36.6 MSEK - Agreement regarding acquisition of Biotage for approximately 230 MSEK
For further information, please contact Jeff Bork Mats-Olof Wallin Chairman of the Board and CEO Chief Financial Officer jeff.bork@pyrosequencing.com mats-olof.wallin@pyrosequencing.com +46 734 22 16 60 +46 705 93 52 73
------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/10/23/20031023BIT00970/wkr0001.doc The full report http://www.waymaker.net/bitonline/2003/10/23/20031023BIT00970/wkr0002.pdf The full report
-0-